Reactions 1704, p335 - 2 Jun 2018 Hepatitis and synthetic liver failure: case report A 39-year-old woman developed hepatitis and synthetic liver failure during treatment with rivaroxaban for deep vein thrombosis (DVT). The woman was commenced on rivaroxaban 20mg daily [route not stated] for deep vein thrombosis of the left peroneus, and developed hepatitis and synthetic liver failure. Her liver function tests were markedly deranged at a clinical review 4 months following the initiation of rivaroxaban. Her ALT, AST, GGT were elevated. ALP was borderline. With the continued elevation in transaminases, synthetic function declined. A liver biopsy showed subacute hepatitis. The presence of multifocal centrilobular perivenular inflammation as well as mononuclear inflammatory infiltrate confirmed the diagnosis of drug-induced liver injury. Rivaroxaban was discontinued after a liver ultrasound confirmed that DVT had resolved. The woman made a rapid recovery thereafter; her laboratory parameters normalised in 4 weeks. Author comment: "We present a case of hepatitis and synthetic liver failure secondary to rivaroxaban". Peverelle M, et al. Drug-induced liver failure due to rivaroxaban. Annals of Hematology 2018: 12 May 2018. Available from: URL: http://doi.org/10.1007/ s00277-018-3364-z - Australia 803322758 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704
Reactions Weekly – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera